BCL2 and B-cell chronic lymphocytic leukemia: More recently, a Bcl-2-selective BH3-mimetic inhibitor was developed, namely ABT-199/venetoclax, which is a very promising anti-cancer drug that has been approved for the treatment of chronic lymphocytic leukemia (80).